<DOC>
	<DOCNO>NCT01693419</DOCNO>
	<brief_summary>This study conduct phase II study gemcitabine , erlotinib , S-1 first-line chemotherapy patient advance pancreatic cancer evaluate EGFR expression , KRAS mutation , BRAF mutation predictive prognostic marker</brief_summary>
	<brief_title>S-1 , Gemcitabine Erlotinib Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Pancreatic ductal adenocarcinoma , also know pancreatic cancer , eighth cause cancer-related death world . The estimated worldwide incidence pancreatic cancer 277,000 case estimate 266,000 patient die disease 20081 . Pancreatic cancer common elderly person young person , characterise early locoregional spread distant metastasis . As result , less 20 % patient diagnosed localize , potentially curable disease , median survival longer 3-4 month without effective treatment2 . Single-agent chemotherapy gemcitabine consider standard care patient advance pancreatic cancer , since Burris et al . demonstrate superiority gemcitabine 5-fluorouracil ( 5-FU ) respect survival benefit well improvement disease relate symptom randomize study3 . Nevertheless , activity gemcitabine monotherapy pancreatic cancer modest , clear need improve efficacy combine anticancer drug . Multiple agent 5-FU4 , capecitabine5,6 , cisplatin7,8 , oxaliplatin9 , pemetrexed10 , irinotecan11 , cetuximab12 , bevacizumab13 , combination gemcitabine test clinical trial , however , fail improve outcome . The agent , combination gemcitabine , show small , statistically significant improvement , hazard ratio ( HR ) 0.82 , absolute improvement median overall survival ( OS ) 5.9 month gemcitabine versus 6.2 month combination , erlotinib , small-molecule inhibitor epidermal growth factor receptor ( EGFR ) 14 . Considering modest improvement survival add erlotinib gemcitabine , new combination therapy great impact urgently need . S-1 oral fluoropyrimidine derivative combine tegafur ( FT ) two modulators ; 5-chloro-2 , 4-dihydroxypyridine ( CDHP ) oteracil potassium ( Oxo ) 1:0.4:1 molar concentration ratio . The phase II trial combination gemcitabine S-1 demonstrate objective response rate 32-48 % median survival 8-12 month 15-17 . Therefore , conduct phase II study gemcitabine , erlotinib , S-1 first-line chemotherapy patient advance pancreatic cancer evaluate EGFR expression , KRAS mutation , BRAF mutation predictive prognostic marker .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pathologically confirm locally advanced unresectable , recurrent metastatic adenocarcinoma pancreas ( Stage IIIIV ; TNM stag system ) Measurable evaluable disease RECIST criterion 1.1 Minimum age 18 year ECOG Performance status 01 Prior adjuvant chemotherapy without gemcitabine , erlotinib S1 allow 4 week elapse since completion chemotherapy . More 4 week since completion prior radiotherapy ( measurable evaluable lesion outside radiation field ) Adequate organ function Patients must sign informed consent indicate aware investigational nature study keep policy hospital . Patients treat previously gemcitabine , erlotinib , S1 adjuvant chemotherapy . Patients CNS metastasis Patients active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , myocardial infarction precede 6 month , pregnancy , breast feeding Any previous concurrent malignancy nonmelanoma skin cancer situ cancer uterine cervix Known history cerebral leptomeningeal metastasis neurologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pancreas neoplasm</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>erlotinib</keyword>
	<keyword>S-1</keyword>
</DOC>